Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates
Published on May 8, 2025
Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.